| Previous Close | 156.14 |
| Open | 155.77 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 155.22 - 155.84 |
| 52 Week Range | 129.20 - 160.92 |
| Volume | 5,583 |
| Avg. Volume | 22,346 |
| Net Assets | 644.51M |
| NAV | 155.30 |
| PE Ratio (TTM) | N/A |
| Yield | 1.24% |
| YTD Return | 10.53% |
| Beta (3y) | 0.96 |
| Expense Ratio (net) | 0.44% |
| Inception Date | 2006-05-01 |
- Market Realist•13 days ago
Behind the Latest Developments for Merck’s Keytruda
Keytruda (pembrolizumab) is a prescription medicine from Merck’s (MRK) immuno-oncology franchise used for the treatment of various tumors.
- Market Realist•16 days ago
This Could Drive Jazz Pharmaceuticals’ Revenue Growth
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of ~$298 million, which represents ~6% growth YoY and ~10% growth QoQ.
- Market Realist•23 days ago
Pfizer’s Sterile Injection Pharmaceuticals in 2Q17 and 1H17
In 1H17, Sulperazon reported revenues of ~$232 million for 15% growth on a YoY basis.
